News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Progen Industries Limited (PGLAF) Meets With FDA To Progress PI-88 Clinical Development


3/27/2006 2:36:54 PM

Progen Industries (ASX: PGL, NASDAQ: PGLAF) is scheduled to meet with the FDA on 5 April to discuss the design of current clinical trials with PI-88 (the company’s most advanced clinical compound) as well as the strategy for future trials. The design of new protocols is important in establishing the potential route to market for PI-88 and as such Progen has maintained an active relationship with the FDA through its Phase II trial program


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES